Larotrectinib RAI Thyroid (LANTERN)
Contact
Description
This study enrolls patients with newly diagnosed differentiated thyroid cancer (papillary thyroid cancer or follicular thyroid cancer) that has spread to the lungs and has a genetic mutation called and NTRK fusion. The study involves taking a study drug called larotrectinib for approximately 6 months prior to receiving radioiodine therapy (RAI). The overall goal of this study is to find out if taking the study drug before RAI works better than receiving RAI alone (the usual standard of care treatment).
Eligibility and criteria
IRB Number:
22-020549
Eligible age range:
Clinical trial phase:
Phase II
Official title:
What to expect
Participants in the research will:
- Receive a study drug called Larotrectinib
- Complete frequent clinic visits at CHOP
- Possibly delay standard of care RAI therapy
- Have periodic imaging performed to evaluate response to treatment
- Have an extra Whole Body Scan (WBS)
- Consume a low iodine diet for 7-14 days before the WBS scan
- Receive a drug called Thyrogen and receive a low dose of radioactive sodium iodine before the WBS scan
Related specialties
Related conditions
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.